These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37294924)

  • 21. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
    Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
    Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity.
    Guo H; Singh I; Wang Y; Deane R; Barrett T; Fernández JA; Chow N; Griffin JH; Zlokovic BV
    Eur J Neurosci; 2009 Mar; 29(6):1119-30. PubMed ID: 19302148
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
    Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sampei Z; Kuramochi T; Sakamoto A; Haraya K; Adachi K; Kawabe Y; Nogami K; Shima M; Hattori K
    Blood; 2014 Nov; 124(20):3165-71. PubMed ID: 25274508
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activated protein C has a regulatory role in factor VIII function.
    Wilhelm AR; Parsons NA; Samelson-Jones BJ; Davidson RJ; Esmon CT; Camire RM; George LA
    Blood; 2021 May; 137(18):2532-2543. PubMed ID: 33512448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia.
    Zhao XY; Wilmen A; Wang D; Wang X; Bauzon M; Kim JY; Linden L; Li L; Egner U; Marquardt T; Moosmayer D; Tebbe J; Glück JM; Ellinger P; McLean K; Yuan S; Yegneswaran S; Jiang X; Evans V; Gu JM; Schneider D; Zhu Y; Xu Y; Mallari C; Hesslein A; Wang Y; Schmidt N; Gutberlet K; Ruehl-Fehlert C; Freyberger A; Hermiston T; Patel C; Sim D; Mosnier LO; Laux V
    Nat Commun; 2020 Jun; 11(1):2992. PubMed ID: 32532974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human factor IX corrects the bleeding diathesis of mice with hemophilia B.
    Kung SH; Hagstrom JN; Cass D; Tai SJ; Lin HF; Stafford DW; High KA
    Blood; 1998 Feb; 91(3):784-90. PubMed ID: 9446637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New therapeutic applications for the anticoagulant, activated protein C.
    Jackson C; Whitmont K; Tritton S; March L; Sambrook P; Xue M
    Expert Opin Biol Ther; 2008 Aug; 8(8):1109-22. PubMed ID: 18613763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid clearing CT-001 restored hemostasis in mice with coagulopathy induced by activated protein C.
    Sim DS; Mallari CR; Bauzon M; Hermiston TW
    J Trauma Acute Care Surg; 2024 Feb; 96(2):276-286. PubMed ID: 37335129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
    Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
    Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activated protein C--an anticoagulant that does more than stop clots.
    Jackson CJ; Xue M
    Int J Biochem Cell Biol; 2008; 40(12):2692-7. PubMed ID: 18249579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and characterization of an APC-specific serpin for the treatment of hemophilia.
    Polderdijk SG; Adams TE; Ivanciu L; Camire RM; Baglin TP; Huntington JA
    Blood; 2017 Jan; 129(1):105-113. PubMed ID: 27789479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
    Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
    Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model.
    Fernández JA; Xu X; Liu D; Zlokovic BV; Griffin JH
    Blood Cells Mol Dis; 2003; 30(3):271-6. PubMed ID: 12737945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting anticoagulant protein S to improve hemostasis in hemophilia.
    Prince R; Bologna L; Manetti M; Melchiorre D; Rosa I; Dewarrat N; Suardi S; Amini P; Fernández JA; Burnier L; Quarroz C; Reina Caro MD; Matsumura Y; Kremer Hovinga JA; Griffin JH; Simon HU; Ibba-Manneschi L; Saller F; Calzavarini S; Angelillo-Scherrer A
    Blood; 2018 Mar; 131(12):1360-1371. PubMed ID: 29317453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1.
    Brummel-Ziedins KE; Whelihan MF; Rivard GE; Butenas S
    J Thromb Haemost; 2011 Nov; 9(11):2262-7. PubMed ID: 21920012
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently.
    Gadi I; Fatima S; Elwakiel A; Nazir S; Mohanad Al-Dabet M; Rana R; Bock F; Manoharan J; Gupta D; Biemann R; Nieswandt B; Braun-Dullaeus R; Besler C; Scholz M; Geffers R; Griffin JH; Esmon CT; Kohli S; Isermann B; Shahzad K
    Circ Res; 2021 Feb; 128(4):513-529. PubMed ID: 33353373
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
    Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
    J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.
    Ivanciu L; Toso R; Margaritis P; Pavani G; Kim H; Schlachterman A; Liu JH; Clerin V; Pittman DD; Rose-Miranda R; Shields KM; Erbe DV; Tobin JF; Arruda VR; Camire RM
    Nat Biotechnol; 2011 Oct; 29(11):1028-33. PubMed ID: 22020385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.
    Gale AJ; Bhat V; Pellequer JL; Griffin JH; Mosnier LO; Von Drygalski A
    Pharm Res; 2016 Jun; 33(6):1517-26. PubMed ID: 26960296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.